ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO256

Emerging Treatment Options for Anemia Associated with CKD: Success of Online Medical Education at Improving Knowledge and Confidence of Nephrologists

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Larkin, Amy, Medscape Education, Nicholasville, Kentucky, United States
  • Anderson, David R., Medscape LLC, New York, New York, United States
  • Badal, Karen, WebMD, New York, New York, United States

As emerging therapies hold promise to improve treatment of anemia in patients with CKD, clinicians are in need of updates on development of new drugs that may ultimately influence their practices. We sought to assess baseline knowledge related to emerging treatments for CKD-related anemia and determine if online continuing medical education (CME) activities could improve the clinical knowledge and confidence of nephrologist in the area of Hypoxia-Inducible Factor Prolyl Hyproxylase Inhibitors (HIF-PHIs).


The effect of two online, CME-certified, roundtable video discussion activities were analyzed to determine efficacy of online education. Three multiple-choice knowledge/competence questions and 1 self-efficacy confidence question were presented both before and immediately after each activity. A repeated pairs pre-/post-assessment study design was used and McNemar’s chi-squared test (5% significance level, P <.05) assessed educational effect for each activity. The activities launched November 18, 2016 and December 21, 2016, and data were collected through December 20, 2016 and February 1, 2017, respectively.


In total, 264 nephrologists answered all pre-/post-assessment questions and were included in the study.

Overall improvements were seen after participation in both CME activities:
10% more nephrologists (P=.035) correctly identified safety and efficacy data for an emerging HIF-PHIs
38% more nephrologists (P<.001) accurately characterized recently released data from a Medicare population of CKD patients
On the 2 activities, 43% (n=126) and 38% (n=138) reported increased confidence in understanding of new therapies in development for the treatment of iron deficiency anemia in patients with CKD

Continued educational gaps:
About a third of nephrologists did not recognize new data presented at a major medical conference related to emerging HIF-PHIs


This study demonstrates the success of online, video-based roundtable discussion on improving knowledge and confidence of nephrologists related to emerging treatments for anemia associated with CKD. Continued knowledge gaps were identified for future educational targets.


  • Commercial Support